Dr. Mascarenhas on Updates from the MANIFEST Trial in Myelofibrosis

John O. Mascarenhas, MD, professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, the Center of Excellence for Blood Cancers and Myeloid Disorders, member, the Tisch Cancer Institute, discusses updates from the phase 2 MANIFEST trial (NCT02158858) in patients with myelofibrosis.

The MANIFEST trial was a randomized, blinded study investigating pelabresib (CPI-0610) as a single agent and in combination with ruxolitinib (Jakafi).

In the third experimental arm, patients who had not been previously treated with a JAK inhibitor received the combination of pelabresib and ruxolitinib, which continued to demonstrate success with 68% of patients achieving a spleen volume reduction of at least 35%, Mascarenhas says. Additionally, 56% of patients saw at least a 50% improvement in total symptom score (TSS), Mascarenhas explains. Compared with historical data of single-agent ruxolitinib, the combination elicited higher efficacy for these patients, Mascarenhas notes.

In the second experimental arm featuring patients who had suboptimal responses to prior treatment with single-agent ruxolitinib, the combination achieved at least a 35% reduction in spleen volume in 30% of patients, and 37% of patients saw at least a 50% improvement in TSS, Mascarenhas concludes.